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Abstract:
Background:
Urinary Tract Infection (UTI) is a common cause of morbidity and mortality in older adults.
Objective:
To investigate antimicrobial resistance of uropathogenic Escherichia coli from elderly patients in a General Hospital, Argentina.
Method:
During the period July 2011-July 2015, patients over 70 years old with urinary tract infections, without urinary catheters and with no
antimicrobial  therapy  the  previous  week  before  sampling,  were  included.  Phenotypic  characterization  was  carried  out.  In  vitro
qualitative and quantitative antimicrobial resistances were investigated. Antimicrobials assayed: ampicillin, amoxicillin-clavulanate,
cefazolin, cefuroxime, cefoxitin, cefotaxime, ceftazidime, cefepime, imipenem, ertapenem, gentamicin, nalidixic acid, ciprofloxacin,
trimethoprim-sulfamethoxazole (TMS) and nitrofurantoin. Patients’ medical records were produced, and risk factors were analyzed
by multivariate analysis.
Results:
768 bacterial isolates were identified as E. coli. Resistances to ampicillin (80.5%), nalidixic acid (61.7%), ciprofloxacin (42.8%),
TMS (37.6%), amoxicillin-clavulanate (28.6%), cefazolin (21.6%), cefuroxime (20.7%), gentamicin (13.8%), cefotaxime (9.7%),
ceftazidime (9.7%), cefepime (8.4%), cefoxitin (3.1%) and nitrofurantoin (2.3%) were observed. Resistance to carbapenems was not
expressed.  Production  of  extended  spectrum  β-lactamases  was  detected  (7.6%)  in  community  acquired  (96%)  and  healthcare
associated  (4%)  isolates.  The  independent  risk  factors  for  urinary  infections  produced  by  multi-resistant  E.  coli  were:  diabetes
mellitus, recurrent infections, hospitalization during the last year and exposure to β-lactams in the last 3 months.
Conclusion:
A high prevalence of resistance to β-lactams and to other antimicrobials was observed. Detection of antimicrobial multi-resistant
isolates highlights the need of antimicrobial resistance surveillance in elderly patients with urinary tract infections.
Keywords: β-lactamases, Elderly patients, Escherichia coli, Infections, Resistance, Urinary tract.
1. INTRODUCTION
Urinary Tract Infections (UTI) can be defined  as the existence  of pathogen microorganisms in  the urinary tract
with symptoms. Amongst UTI, bacterial etiology (80-90%) is the most frequent. UTI are responsible for an estimated
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7 million office visits, 1 million emergency room visits, and 100,000 hospitalizations each year, accounting for 25% of
all infections in geriatric patients [1, 2].
Increased incidence of UTI in elderly patients is due to their immune status and the physiological and anatomical
changes  linked  with  aging.  While  urinary  sepsis-associated  deaths  are  globally  low,  in  elderly  patients  with  UTI´s
bacteremia, it can reach prevalence rates around 33% [3].
Escherichia  coli  is  one  of  the  bacterial  agents  with  higher  prevalence  in  community-acquired  and  health  care
associated urinary infections in elderly patients, followed by other Enterobacteriaceae such as Klebsiella spp., or Gram
positive bacteria [4 - 7].
Worldwide,  a  rise  of  Extended  Spectrum Beta-Lactamase  (ESBL)  producing  E.  coli  and  multi-resistant  solates
(show resistance to, at least, three antimicrobials from different groups or families of these pharmacological agents). has
been reported. This antimicrobial resistance mechanism is highly prevalent in Gram negative bacteria, with significant
relevance for Public Health because of its horizontal spread [5, 8 - 11]
Emergence  and  fast  dissemination  of  ESBL-producing  uropatohgenic  E.  coli  has  resulted  in  an  increase  of  the
employment of carbapenems and non-β-lactams. Usage of these antimicrobial drugs has caused a rise in the prevalence
of carbapenemase-synthesizing bacterial strains, and an alarming increase in antimicrobial resistance rates for drugs
such as fluoroquinolones and aminoglycosides [2].
Due to comorbility factors, people over 70 years old are frequent users of Public Health settings. This exposes them
to a high consumption of antimicrobial drugs widely used for the treatment of infections, which leads to an increment of
resistance to these antimicrobial agents. Elderly patients are expected to show a higher incidence of UTI; since it has
been proven that it increases with aging [12].
In  Argentina,  for  elderly  patients,  E.  coli  is  the  most  frequently  multi-resistant  bacteria  associated  with  UTI.
Resistance profiles of these strains include antimicrobials widely used for infections therapy. However, there is scarce
recent information about elderly patients with community-origin UTI [13].
The aim of this study was to investigate antimicrobial resistance of uropathogenic Escherichia coli from elderly
patients in a General Hospital, Argentina.
2. MATHERIAL AND METHODS
2.1. Study Design
During the period July 2011-July 2015, an observational, prospective study was carried out.
2.2. Epidemiology of Patients and Clinical Setting
Patients with the following criteria were included: over 70 years old, with no urinary catheters, no antimicrobial
therapy the previous week before sampling, attending a General Hospital in Tandil (Argentina), presenting UTI´s signs
and symptoms and having only monomicrobial cultures.
In Tandil, Argentina, there is a Public Health system that assists the population of the central region of the Buenos
Aires province, including the city of Tandil and its surrounding districts. This region comprises middle-sized cities and
small towns, as well as rural settings.
Over 40% of the district´s population attends Public Health system facilities. During the last years, a significant
increase of elderly patients at the district´s General Hospital has been registered. Most of these patients are female and
male over 70 years old people with documented comorbidities such as diabetes mellitus, recurrent UTIs, history of
hospitalization, chronic renal failure, autoimmune diseases and exposure to antimicrobials widely used in the clinical
settings (e.g β-lactams and quinolones).
2.3. Sampling and Initial Microbiological Processing
Urine samples, N: 3,920 (from every July to the following June, each period had 980, 930, 995 and 1015 urine
samples respectively obtained under medical prescription), were sent to the Microbiology laboratory for their analysis.
An initial isolation for Enterobacteriaceae was performed in a selective and differential culture media, EMB Levine
agar (Lab. Britania, Buenos Aires, Argentina). For Gram positive cocci, initial cultures were carried out in Triptein Soy
Agar (Lab. Britania), sheep blood-agar (Lab. Britania), and Sabouraud-dextrose agar (Lab. Britania) for yeasts. Isolates
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were stored (-70ºC) by triplicate in Brain Heart Infusion broth (Lab. Britania) with glycerol (30%).
2.4. Phenotypic Characterization
Phenotypic  characterization of  isolates  at  species  level  was carried out  with biochemical  tests  [14].  VITEK 2®
Compact automated system (BioMérieux, Buenos Aires, Argentina) was used for the validation of characterization.
2.5. Antimicrobial Susceptibility Testing
Disk  diffusion  method:  In  vitro  qualitative  antimicrobial  resistance  profiles  were  investigated  according  to  the
Clinical and Laboratory Standards Institute´s recommendations, CLSI [15]. Assayed disks (Lab. Britania): ampicillin
(10 μg), Amoxicillin-clavulanate (20/10 μg), cefazolin (30 μg), cefuroxime (30 μg), cefoxitin (30 μg), cefotaxime (30
μg), ceftazidime (30 μg), cefepime (30 μg), imipenem (10 μg), ertapenem (10 μg), gentamicin (10 μg), nalidixic acid
(30 μg), ciprofloxacin (5 μg), trimethoprim-sulfamethoxazole (TMS, 1.25/23.75 μg) and nitrofurantoin (300 μg).
Minimum Inhibitory Concentration (MIC): it was determined by the broth microdilution method according to CLSI
[15]. Quality control strains: E. coli ATCC 25922, E. coli ATCC 35218 and Pseudomonas aeruginosa ATCC 27853.
2.6. Detection of ESBL
For detection of ESBL in E. coli,  disk diffusion method was performed in Mueller-Hinton agar (Lab. Britania),
employing  cefotaxime,  cefotaxime-clavulanate  (30/10  μg),  ceftazidime  and  ceftazidime-clavulanate  (30/10  μg),
respectively.  A  ≥  5-mm increase  in  diameter  for  either  antimicrobial  agent  tested  in  combination  with  clavulanate
versus the diameter of the agent when tested alone was considered as an ESBL´s producer isolate [15].
2.7. Definition of Urinary Tract Infection
Symptomatic  UTI  in  older  adults  is  defined  as  the  presence  of  localized  genitourinary  symptoms,  urinary  tract
inflammation demonstrated by leukocyturia, and a urine culture with an identified urinary pathogen, with a minimum
level of bacteriuria of 103 cfu/mL. Recurrent UTI refers to ≥2 infections in six months or ≥3 infections in one year [16,
17].
2.8. Epidemiological Features
Patients’  medical  records  were  produced.  With  the  reception  of  each  urine  sample  a  pre-designed  form  was
completed. It included the following data: gender, diabetes mellitus, recurrent urinary tract infection, hospitalization in
the last year, chronic kidney disease, autoimmune disease and exposure to antimicrobials in the last 3 months (global
expousure and specific expousure to β-lactams and quinolones).
2.9. Statistical Analysis of Epidemiological Features from Patients
XLSTAT  (version  2018.1)  software  package  was  used  for  the  analysis  of  patients´  epidemiological  features.
Potential risk factors for ESBL-producing E. coli UTI were identified by univariate analysis. Multi-variate analysis was
performed by a multiple regression test and Odd Ratios (OR) with a confidence interval (95%) were calculated by a
logistic regression test. Ratio was calculated for the variable genre. Categorical variables were expressed in absolute
numbers  and  percentages.  The  Chi-square  test  was  used  for  categorical  variables.  Independent  risk  factors  were
determined. p < 0.05 values were considered as statistically significant.
3. RESULTS
Of  the  analyzed  urine  samples,  n:  1,024  were  positive  with  one  cultured  microorganism.  In  patients  with
monomicrobial cultures, etiological agents of urinary infections were initially characterized as Gram negative bacilli
(88%), Gram positive cocci (9%) and yeasts (3%). Phenotypic characterization showed that n: 768 bacterial isolates
were identified as E. coli (75%).
Amongst  this  bacterial  species,  335/768  (43.6%)  isolates  were  multi-resistant  to  antimicrobials,  while  433/768
(56.4%) showed susceptibility or non-multiple resistance. Non multi-resistant E. coli expressed resistance to: β-lactams
alone (176, 40.7%), β-lactams and quinolones (82, 18.9%), quinolones alone (81, 18.7%), β-lactams and TMS (36,
8.3%), TMS alone (13, 3%), aminoglycosides and quinolones (1, 0.2%), and resistance to no antimicrobial (44, 10.2%).
Highest antimicrobial resistance prevalence frequencies were detected for β-lactams, followed by quinolones.
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Uropathogenic  E.  coli  isolates  showed  resistance  to  ampicillin  (618/768),  cefazolin  (166/768),  nalidixic  acid
(474/768),  ciprofloxacin  (329/768),  TMS  (289/768),  amoxicillin-clavulanate  (220/768),  cefuroxime  (159/768),
gentamicin  (106/768),  cefoxitin  (24/768),  cefotaxime  (74/768),  ceftazidime  (74/768),  cefepime  (65/768)  and
nitrofurantoin (18/768). Resistance to imipenem and/or ertapenem was not observed in any of the investigated E. coli
(Table 1).
Table 1. Antimicrobial resistance in Escherichia coli isolated from elderly patients with urinary tract infections.
ATM I (%) R (%) MIC Range (µg/mL) MIC50(µg/mL)
MIC90
(µg/mL)
Ampicillin 0 80.5 ≤2-64 32 64
AMCa 3.1 28.6 ≤2-64 4.0 64
Cefazolin 46.2 21.6 ≤1-64 4.0 32
Cefuroxime 0 20.7 1-32 2.0 32
Cefoxitin 11.2 3.1 1-32 1.0 32
Cefotaxime 0 9.7 ≤1-64 0.25 2.0
Ceftazidime 0 9.7 ≤4-64 0.25 2.0
Cefepime 0 8.4 0.5-32 0.50 8.0
Ertapenem 0 0 ≤0.25-0.5 0.12 0.5
Imipenem 0 0 ≤0.25-1 0.12 0.50
Gentamicin 0.9 13.8 ≤0.5-128 0.50 64
Nalidixic acid 0.1 61.7 ≤16-64 32 64
Ciprofloxacin 3.0 42.8 ≤0.25-8 0.12 8.0
TMSb 0.1 37.6 2-320 2.0 160
Nitrofurantoin 0 2.3 2-128 4.0 32
ATM,  antimicrobial;  I,  intermediate  susceptibility;  R,  resistance;  AMC,  amoxicillin-clavulanate;  TMS,  trimethoprim-sulfamethoxazole.  MIC,
Minimum inhibitory concentration. aFor MICs determination, the concentration of clavulanic acid was fixed at 2 µg/mL. bTMS in the ratio 1:19. MICs
values are expressed as the trimethoprim concentration.
In  addition,  in  7.6% of  the  resistant  isolates  the  production  of  ESBL was  detected.  Most  of  the  enzymes  were
synthesized by community acquired E. coli (96%).
Also, patients´ epidemiological features were analysed in order to detect independent risk factors of UTI produced
by E. coli (Table 2).
Table  2.  Epidemiological  features  and  statistical  analysis  of  elderly  patients  with  urinary  tract  infections  produced  by
Escherichia coli.
Antimicrobial Resistance Phenotype







Female patients (F:M) 323 (2.9:1) 207 (1.6:1) 0,64 (0.45-0.92) 0.019
Diabetes mellitus (%) 25 (5.8) 68 (20.3) 4.56 (2.95-7.05) <0.0001
Recurrent urinary tract infections (%) 37 (8.5) 108 (32.2) 2.94 (1.94-4.45) <0.0001
Hospitalization during the last year (%) 53 (12.2) 123 (36.7) 2.37 (1.23-4.57) 0.0076
Chronic renal failure (%) 17 (3.9) 63 (18.8) 1.52 (0.52-4.38) 0.5987
Autoimmune disease (%) 8 (1.8) 25 (7.5) 0.25 (0.06-1.05) 0.0779
Exposure to antimicrobials in the last 3 months (%) 73 (16.9) 132 (39.4) 1.23 (0.64-2.37) 0.4671
Exposure to β-lactams in the last 3 months (%) 36 (8.3) 98 (29.3) 2.68 (1.36-5.26) 0.0027
Exposure to quinolones in the last 3 months (%) 52 (12) 93 (27.8) 1.05 (0.72-1.51) 0.8477
OR, odd ratio. CI, confidence interval. p values < 0.05 are showed in cursive letter. F:M. female/male patients ratio.
According to the statistical  analysis,  independent  risk factors  for  UTI produced by multi-resistant  E. coli  were:
diabetes mellitus (OR 4.56, 95% CI 2.95-7.05), recurrent UTI (OR 2.94, 95% CI 1.94-4.45), hospitalization during the
last year (OR 2.37 95% CI 1.23-4.57) and exposure to β-lactams in the last 3 months (OR 2.68 95% CI 1.36-5.26).
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4. DISCUSSION
Over the last years, in South America, predominance of Gram negative bacilli as etiological agents of UTI has been
reported [16, 17]. In Argentina, a previous study reported that 76.3% of UTI in outpatients and hospitalized patients
were associated with Gram negative bacilli, where 62.7% of the isolates were identified as E. coli. In a more recent
investigation, E. coli was responsible for 67.7% of the community-acquired UTI [13, 18].
In this study, in 100% of the analyzed strains, resistance to imipenem or ertapenem was not detected. Previously, in
Argentina, other authors have communicated the abscense of resistance to carbapenems in E. coli from patients over 65
years old with UTI [13].
Uropathogenic E. coli isolates showed resistance to ampicillin (80.5%) and to ampicillin-clavulanate (28.6%). In
Argentina,  during 2013,  in  a  general  hospital  a  lower  prevalence  of  ampicillin  resistance  (70.5%) was  observed in
patients with community-onset UTI caused by E. coli, while a higher frequency of ampicillin-sulbactam resistance was
reported (52.7%). Conversely, in Uruguay, in low-UTI patients, lower percentages of ampicillin (52%) and ampicillin-
sulbactam resistance were detected for E. coli. A similar prevalence of ampicillin resistance (ca. 80%) was observed for
uropathogenic Gram negative bacilli isolated from non-hospitalized elderly in Italy [13, 16, 19].
Resistance (21.6%) to cefazolin in the studied isolates was observed. In UTI-producing E. coli from Colombia, a
higher resistance (42.8%) to first-generation cephalosporins in primary care patients was detected.  In Argentina,  in
another  surveillance  study  that  included  E.  coli  recovered  from  2004  to  2007,  resistance  to  first-generation
cephalosporins  ranged  from  6.8%  to  15.8%  [17,  18].
Cefoxitin  resistance  (3.1%)  was  detected  in  this  study.  In  Colombian  patients,  E.  coli  showed  slightly  higher
resistance to cephalotin (4.8%). During the years 2005, 2009 and 2011, in Spanish patients with UTI produced by E.
coli, resistance to this antimicrobial comprised a range from 1.7% to 8.2%, with lower and higher frequencies than the
isolates included in this investigation [20, 21].
Resistance  to  cefuroxime was  expressed  by  20.7% of  the  uropathogen E.  coli  isolated  from elderly  patients.  A
significant  lower  prevalence  (1%)  was  communicated  for  patients  with  community-acquired  low-UTI  in  Uruguay.
However, in urinary E. coli from Colombian patients, cefuroxime resistance was considerably higher (63%) than the
reported in this study [16, 22]. A mean cefuroxime resistance of 17.7% was observed in uropathogen E. coli isolates
from Mexico.  In  addition,  resistance  (27%) to  this  second-generation cephalosporin  was  expressed by community-
acquired E. coli recovered from Cuban patients [23, 24].
In this study, resistance to cefotaxime (9.7%) and ceftazidime (9.7%), in E. coli was observed. A recent surveillance
carried out in Argentina, showed a higher prevalence of cefotaxime (12.9%) and ceftazidime (10.2%) in E. coli from
elderly  patients  with  UTI  [13].  In  a  previous  research  carried  out  in  Romania,  20% of  the  elderly  patients  studied
expressed resistance to ceftazidime. A different epidemiological situation was seen in community-onset UTI patients´
from Uruguay, where E .coli showed no resistance to third-generation cephalosporins [16, 25].
Cefepime-resistant E. coli (8.4%) were recovered from elderly patients with UTI. When prevalence of community-
acquired UTI produced by Enterobacteriaceae was investigated, in a US-prospective-observational study that analyzed
the occurrence of UTI by community-acquired E. coli, 12.5% of the isolates showed resistance to cefepime [9].
In  this  research,  resistance  to  gentamicin  was  detected  (13.8%).  Previously,  a  higher  frequency  of  gentamicin
resistance  (22.6%)  was  reported  for  E.  coli  in  elderly  Argentinian  patients  and  in  Enterobacteriaceae  from Italian
elderly (over 30%). In contrast, a significantly lower average prevalence (3.7%) of gentamicin resistance was detected
during a 5-year period for community urinary E. coli isolates from Australia [13, 19, 26].
Nalidixic acid (61.7%) and ciprofloxacin (42.8%) were the most prevalent among non-β-lactams antimicrobials. In
Argentina,  from  2009  to  2013,  an  increasing  ciprofloxacin  resistance  frequency  (20-29.8%)  was  detected  in  UTI-
producing E. coli. In 2017, 51.9% of UTI in non-hospitalized elderly patients were reported to be caused by E. coli
resistant to this drug [13, 18]. In Italy and Romania, ciprofloxacin resistance presented a similar prevalence than the one
in  this  study,  41.4%  and  over  50%,  respectively.  In  Brazil,  33/49  nalidixic-resistant  E.coli  isolates  also  expressed
resistance to ciprofloxacin, showing that nalidic acid is still a marker for quinolones susceptibility [19, 25, 27]
Resistance to TMS was osberved by E.coli  isolates in this investigation (37.6%). In Argentina, on recent years,
resistance to this antimicrobial showed a preavalence range between 28.1% and 45.7% in eldery patients with UTI.
However, at continental level, higher rates of resistance were informed, as was the case of low-UTI strains (70%) in
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Uruguay. In Australia, the main resistance prevalence to trimethoprim from 2009 to 2013 was still lower (20.6%) than
what was reported in this research [13, 16, 18, 26].
In this study, the lowest antimicrobial resistance prevalence was observed for nitrofurantoin (2.3%). Other studies
carried  out  in  South  and  Central  America  reported  frequencies  of  nitrofurantoin  resistance  below  10%  in  E.  coli
identified as etiologic agents of UTI, as was communicated in Argentina (0.9-6%), Colombia (4.2%) and Cuba (1.8%).
However, in Mexico, in community-acquired UTI it was shown that resistance to this antimicrobial was higher (40%)
than the reported in this investigation [16, 17, 23, 24].
Production of ESBL (96%, community origin and 4% health-care associated origin) was detected in 7.6% of E. coli
isolates. In Mexico, it was reported that 10.2% of 4,375 E. coli identified as agents of community-acquired UTI was
ESBL-producing strains. In other countries from the northern hemisphere, prevalence of ESBL-producing E. coli was
higher (36.8%, US) or similar (8.7%, Spain) to the ESBL frequency communicated in this study. On the contrary, in
Australia ESBL production until 2013 still remained significantly lower (1.9%) than in Argentina or other American
countries [9, 10, 21, 26].
In  this  research,  independent  risk  factors  for  UTI  produced  by  multi-resistant  E.  coli  were:  diabetes  mellitus,
recurrent  UTI,  hospitalization  during  the  last  year  and  exposure  to  β-lactams  in  the  last  3  months.  A retrospective
case–control study carried out in an Australian tertiary referral hospital during 2003 to 2009 discovered that the factors
associated with UTI produced by ESBL-Gram negative bacteria were: recent travels, previous exposure to antibiotics,
residency at a nursing home, and length of hospital inpatient [28].
In a prospective cohort study, conducted from December 2010 to January 2012, a total of 376 patients were enrolled
and 393 isolates from urine culture were analyzed; nasogastric tube placement and hospitalization within the previous 3
months were statistically significant for the acquisition of ESBL-producing pathogens in community-onset UTI [29].
Elderly patients are more likely to be immunocompromised, have co-morbidities, are hospitalized more frequently
than younger patients and are more likely to develop infections with multi-drug resistant pathogens [30]. For similar
reasons, patients with diabetes are at risk of recurrent UTIs that, over time, pose more risk of resistances [31, 32].
A  common  and  preventable  risk  factor  for  multi-drug  resistant  UTIs  is  the  prior  use  of  antimicrobials.  In  our
investigation, exposure to β-lactams in the last 3 months was an independent risk factor for multi-resistant E. coli´s
ITU.  Recent  studies  have  demonstrated  that  the  use  of  antimicrobials  from 4  weeks  to  1  year  preceding  the  index
infection increases the probability of multi-drug resistance. Uses of fluoroquinolones and anti-pseudomonal penicillin,
as well as more cumulative days of treatment with any antimicrobial prior to UTI presentation, were most strongly
associated with resistance [30 - 32].
CONCLUSION
In this study, a high prevalence of resistance to β-lactams as well as to other antimicrobials were observed in E. coli
isolates from elderly patients with UTI. Statistical analysis of patients´ epidemiological features showed the existence of
independent risk factors for UTI produced by multi-resistant E.coli. Based on the results of this research. we suggest to
avoid  using  quinolones  or  TMS for  patients  older  than  70  years  old  with  at  least  one  of  the  previously  mentioned
independent risk factors. These findings might help physicians to choose empirical antibiotics in an overall high-rate
setting of ESBL-producing E. coli. Detection of these strains represents an alarm signal that motivates a continuous
surveillance of antimicrobial resistance in adult patients with urinary infections produced by E. coli.
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